The Impact of Acute Urinary Retention After Iodine-125 Prostate Brachytherapy on Health-Related Quality of Life
Creators
- 1. Department of Radiation Oncology, University Medical Center Utrecht, Utrecht (Netherlands)
- 2. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht (Netherlands)
- 3. Department of Urology, University Medical Center Utrecht, Utrecht (Netherlands)
- 4. Department of Radiation Oncology, M. D. Anderson Medical Center, Houston, TX (United States)
Description
Purpose: To evaluate the impact of acute urinary retention (AUR) in patients treated with 125I prostate brachytherapy on short- and long-term health-related quality of life (HRQOL); and to assess whether pretreatment HRQOL has additional value in the prediction of AUR. Methods and Materials: For 127 patients treated with 125I brachytherapy for localized prostate cancer between December 2000 and June 2003, toxicity and HRQOL data were prospectively collected. Patients received a HRQOL questionnaire at five time points: before and 1 month, 6 months, 1 year, and 6 years after treatment. The questionnaire included the RAND-36 generic health survey, the cancer-specific European Organization for Research and Treatment of Cancer core questionnaire (EORTC QLQ-C30), the tumor-specific EORTC prostate cancer module (EORTC QLQ-PR25), and the American Urological Association (AUA) symptom index. Results: Of 127 patients, 13 (10.2%) developed AUR. Patients with AUR had a significantly worse urinary QOL at all time points compared with patients without AUR. The mean difference over time (6 years) between both groups for the EORTC QLQ-PR25 urinary symptom score was 13.0 points (p < 0.001) and for the AUA urinary symptom score was 15.7 points (p = 0.001). Global QOL scores (EORTC QLQ-C30) over time for patients who developed AUR were significantly worse compared with patients without AUR (mean difference 6.7 points; p = 0.043). In multivariate logistic regression analysis, pretreatment International Prostate Symptom Score (p = 0.004) and neoadjuvant hormonal treatment (p = 0.034) were predictors of AUR. Quality of life did not have added predictive value. Conclusion: Acute urinary retention after prostate brachytherapy has a significant negative impact on patient's HRQOL up to 6 years after treatment, in terms of both global QOL measures and urinary symptom scores. Furthermore, our results suggest limited value of pretreatment HRQOL measures for the prediction of AUR.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.ijrobp.2009.06.083Additional details
Identifiers
- DOI
- 10.1016/j.ijrobp.2009.06.083;
- PII
- S0360-3016(09)02796-5;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 77
- Journal Issue
- 5
- Journal Page Range
- p. 1322-1328
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 42046047
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- BRACHYTHERAPY; IODINE 125; NEOPLASMS; PROSTATE; RETENTION; STANDARD OF LIVING; URINE
- Descriptors DEC
- BETA DECAY RADIOISOTOPES; BIOLOGICAL MATERIALS; BIOLOGICAL WASTES; BODY; BODY FLUIDS; DAYS LIVING RADIOISOTOPES; DISEASES; ELECTRON CAPTURE RADIOISOTOPES; GLANDS; INTERMEDIATE MASS NUCLEI; INTERNAL CONVERSION RADIOISOTOPES; IODINE ISOTOPES; ISOTOPES; MALE GENITALS; MATERIALS; MEDICINE; NUCLEAR MEDICINE; NUCLEI; ODD-EVEN NUCLEI; ORGANS; RADIOISOTOPES; RADIOLOGY; RADIOTHERAPY; THERAPY; WASTES
Optional Information
- Copyright
- Copyright (c) 2010 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.